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Abstract 
© Journal of Gastrointestinal Oncology. All rights reserved. Background: The impact of increased body 
mass index (BMI) on clinical outcomes in locoregional rectal cancer is unknown. Methods: This is a 
retrospective cohort study which included 453 consecutive rectal cancer patients undergoing definitive 
treatment, with confirmed stage I, II or III rectal adenocarcinoma. The association of BMI at diagnosis 
with overall survival (OS), cancer specific survival (CSS) and disease-free survival (DFS) was explored, 
controlling for key covariates using multivariable analyses. BMI as defined by the World Health 
Organization (WHO) is as follows: BMI <18.5-underweight; 18.5-24.9-normal; 25.0-29.9-pre-obesity; 
>30-obese. Results: Overweight and obese patients had significantly better OS than underweight/normal 
weight patients (5-year OS 80% for overweight, 77% for obese, and 65% for underweight/normal weight 
patients, P=0.02). High BMI (>25) was significantly associated with improved OS in univariate [0.62 
(0.4-0.8) P=0.007] and multivariable [0.65 (0.4-0.9) P=0.023] analyses. When stratified by stage, high BMI 
was associated with improved OS in stage III patients (P=0.0009), but not stage II (P=0.21) or stage I 
(0.54). High BMI was also significantly associated with improved CSS in univariate (HR 0.62, P=0.048) 
and multivariable analyses (HR 0.58, P=0.03). Conclusions: In our study a BMI greater than 25 is 
significantly associated with a longer OS and CSS in patients with locoregional rectal cancer. These 
findings may be due to the reduced metabolic capacity for non-obese patients to deal with rectal cancer 
treatment as well as the burden of disease, however further research is needed to evaluate this. 
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Background: The impact of increased body mass index (BMI) on clinical outcomes in locoregional rectal 
cancer is unknown. 
Methods: This is a retrospective cohort study which included 453 consecutive rectal cancer patients 
undergoing definitive treatment, with confirmed stage I, II or III rectal adenocarcinoma. The association of 
BMI at diagnosis with overall survival (OS), cancer specific survival (CSS) and disease-free survival (DFS) 
was explored, controlling for key covariates using multivariable analyses. BMI as defined by the World 
Health Organization (WHO) is as follows: BMI <18.5—underweight; 18.5-24.9—normal; 25.0-29.9—pre-
obesity; >30—obese. 
Results: Overweight and obese patients had significantly better OS than underweight/normal weight 
patients (5-year OS 80% for overweight, 77% for obese, and 65% for underweight/normal weight patients, 
P=0.02). High BMI (>25) was significantly associated with improved OS in univariate [0.62 (0.4–0.8) 
P=0.007] and multivariable [0.65 (0.4–0.9) P=0.023] analyses. When stratified by stage, high BMI was 
associated with improved OS in stage III patients (P=0.0009), but not stage II (P=0.21) or stage I (0.54). High 
BMI was also significantly associated with improved CSS in univariate (HR 0.62, P=0.048) and multivariable 
analyses (HR 0.58, P=0.03). 
Conclusions: In our study a BMI greater than 25 is significantly associated with a longer OS and CSS in 
patients with locoregional rectal cancer. These findings may be due to the reduced metabolic capacity for 
non-obese patients to deal with rectal cancer treatment as well as the burden of disease, however further 
research is needed to evaluate this.
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Introduction
Colorectal cancer is a common and lethal malignancy, 
accounting for an estimated 12.3% of all new cancers 
diagnosed in 2018 and estimated 8.5% of all deaths from 
cancer in 2018 in Australia (1). Obesity, as reflected by a 
high body mass index (BMI), is a known risk factor for the 
development of colorectal cancer (2). It has also been shown 
to contribute to greater morbidity and short term post-
operative complications in colorectal surgery (3). However, 
the impact of BMI on longer term clinical outcomes in 
locoregional rectal cancer is uncertain with conflicting 
results from published studies. While some surgical series 
demonstrate improved overall survival (OS) in overweight 
and obese patients compared with underweight patients 
(4-7), other studies have contrasting results with a decreased 
survival seen in overweight/obese patients (8,9), or no 
difference in OS across BMI categories (10-14).
In Australia, as well as an increasing incidence of rectal 
cancer, we are also experiencing an increasing incidence of 
obesity (15,16). A Queensland study (17) investigated the 
impact of weight on mortality using data from 1,825 patients 
diagnosed with stage I-III colorectal cancer. They 
demonstrated that overweight, but not obese patients, 
had an improved OS compared to those with a normal 
BMI. Underweight patients had a significantly higher 
mortality risk. They also found that excessive weight loss 
of five kilograms or more at any period was associated with 
increased all-cause and colorectal cancer-specific mortality. 
We undertook this study to evaluate how BMI affects 
OS, cancer specific survival (CSS) and disease-free survival 
(DFS) in locoregional rectal cancer receiving curative 
treatment. We present the following article in accordance 
with the STROBE reporting checklist (available at http://
dx.doi.org/10.21037/jgo-20-48).
Methods
Patient cohort
Using electronic medical records and cancer registry data, 
we identified all patients with histopathological confirmed 
stage I, II or III rectal adenocarcinoma, undergoing 
definitive treatment, that were managed in the Illawarra 
Shoalhaven Local Health District (New South Wales, 
Australia) between 2006-2017. Staging was based on the 
8th edition of the American Joint Committee on Cancer 
and College of American Joint Pathologists (AJCC) (18). 
Staging was based on clinical stage for patients undergoing 
neoadjuvant therapy, or pathological stage for patients who 
had surgery upfront. Patients managed with non-curative 
or palliative intent were excluded. A total of 453 patients 
managed with curative intent were included in the analysis, 
regardless of neoadjuvant or adjuvant treatments. For each 
patient the following was extracted from the medical record: 
age, gender, TNM stage, presence of lymphovascular (LVI) 
or perineural (PNI) invasion, histopathological grade, BMI, 
length of stay (LOS), type of surgery, pretreatment CEA, 
neoadjuvant/adjuvant radiotherapy and chemotherapy, and 
long term outcomes including OS, CSS, and DFS. BMI 
was collected at diagnosis of rectal cancer, and defined by 
the World Health Organization (WHO) is as follows: BMI 
<18.5—underweight, BMI 18.5–24.9—normal weight, BMI 
25.0–29.9—pre-obesity, BMI >30—obese (19). BMI was 
collected at the time of diagnosis.
The research was conducted in accordance with 
the Declaration of Helsinki (as revised in 2013) lsinki. 
This study was approved by the NSW Population & 
Health Services Research Ethics Committee (LNR/15/
WGONG/61). 
Statistical analysis
Our primary outcome was impact of BMI on all cause OS. 
The secondary outcomes were CSS, DFS, and surgical 
complications measured by LOS. Patient characteristics 
were compared with ChiSq. Median values for OS, CSS, 
and DFS, and corresponding 95% CI were calculated using 
Kaplan-Meier methods. Unadjusted and multivariable 
Cox proportional hazards regression analyses were used 
to estimate the association between BMI and survival 
outcomes, and to calculate corresponding hazard ratios 
(HRs) and 95% confidence intervals (CIs). All variables 
significant in the univariate analysis (P<0.05) were included 
in the multivariable model. All statistical analyses were 
performed using SAS 9.2 software (SAS Institute, Inc., 
Cary, NC, USA). 
Results
Patient characteristics (n=453)
The characteristics of the included patients are summarized 
in Table 1. The mean follow-up was 3.2 years. At the end of 
the follow-up period, 144 (32%) patients had died, with 79 
deaths (55% of deaths) due to rectal cancer. One hundred 
and twenty-four (27%) patients had local recurrence or 
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distal metastases from their disease. Four (1%) patients were 
underweight, 120 (26%) patients had a normal BMI, 198 
(44%) were overweight, and 131 (29%) were obese, similar 
to reported demographics of the Australian population 
(15,16). The weight groups had similar demographic and 
clinicopathological characteristics, apart from pre-treatment 
CEA which was less likely to be elevated in overweight and 
obese patients compared to underweight/normal weight 
patients (20% vs. 32%, P=0.0079). There was no significant 
difference in use of laparoscopic surgery, neoadjuvant 
radiotherapy or adjuvant chemotherapy, or postoperative 
LOS between BMI groups (Table 1).
BMI and survival outcomes
Overweight and obese patients had significantly better OS 
than underweight/normal weight patients (5-year OS 80%, 
77%, 65% respectively, P=0.02). As there was no significant 
difference in survival outcomes between overweight and 
obese patients, these groups were combined for subsequent 
analyses. In univariate analysis, BMI >25 was associated with 
improved OS (HR 0.62; 95% CI, 0.4–0.8, P=0.007) (Table 2, 
Figure 1). In multivariable analysis, after adjusting for age, 
TNM stage, tumour grade, receipt of chemotherapy, and 
LVI, high BMI remained significantly associated with 
Table 1 Patient characteristics [n=453]
Patient characteristics All patients 
Underweight/normal weight 
(BMI ≤25), N=124
Overweight /obese  
(BMI >25), N=329
P value
Age
<65 171 [38] 50 [40] 121 [37] 0.05
65–75 151 [33] 31 [25] 120 [36]
>75 131 [29] 43 [35] 88 [27]
Male sex 297 [66] 74 [60] 223 [67] 0.10
TNM stage
I 124 [27] 28 [23] 96 [29] 0.28
II 89 [18] 21 [17] 60 [18]
III 248 [55] 75 [60] 173 [53]
High grade 41 [10] 13 [11] 28 [9] 0.53
LVI presenta 85 [19] 26 [22] 59 [19] 0.41
PNI presentb 79 [18] 25 [21] 54 [17] 0.35
BMI
Underweight (<18.5) 4 [1] 4
Normal (18.5–25) 120 [26] 120
Overweight [25–30] 198 [44] 198
Obese (>30) 131 [29] 131
Pre-treatment CEA
≤5 346 [76] 84 [68] 262 [80] 0.0079
>5 107 [24] 40 [32] 67 [20]
Laparoscopic surgery 83 [18] 28 [23] 55 [17] 0.15
Neoadjuvant radiotherapy 172 [38] 54 [44] 118 [36] 0.10
Adjuvant chemotherapy 172 [38] 49 [39] 123 [37] 0.70
Median length of stay (days) 10 10 10
a
, 27 results missing; 
b
, 16 results missing.
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improved OS (HR 0.65; 95% CI, 0.4–0.9, P=0.023). When 
stratified by stage, high BMI was associated with improved 
OS in stage III patients (P=0.0009), but not stage II (P=0.21) 
or stage I (0.54). High BMI (>25) was also significantly 
associated with CSS in univariate (HR 0.62; 95% CI, 0.4–
0.99, P=0.048), and multivariable analyses (HR 0.58; 95% 
CI, 0.3–0.98, P=0.03) (Figure 1).
There was no significant association of BMI and DFS 
(HR 0.71; 95% CI, 0.5–1.1, P=0.08) (Figure 1). Similarly, 
overweight and obese patients had no significant increased 
risk of local recurrence compared to normal/underweight 
patients (6% vs. 7%, P=0.64).
Discussion 
The central finding of our study is that overweight and 
obese patients had significantly better OS than underweight/
normal weight patients (5-year OS 80%, 77%, 65% 
respectively). This association persisted after adjustment 
for known confounders on multivariable analyses. Similar 
results have been demonstrated by other studies in 
colorectal cancer. Shahjehan et al. (4) found underweight 
patients had poorer survival in patients with stage III and 
IV disease, while Ballian et al. (6) showed improved survival 
in obese rectal cancer patients. Similar results were seen by 
You et al. (7), who found the 5-year disease free survival rate 
was lower in the underweight patients and higher in the 
obese patients with upper rectal cancer.
However, there are conflicting results in the literature, 
with other studies finding no impact of BMI on CSS (12), 
OS (13,14), or DFS (13). One series examining patients with 
locoregional rectal cancer in Mexico showed an inferior DFS 
in obese patients, although these results may be due reduced 
utilization of neoadjuvant treatments in this group (8). 
In our study, clinicopathological characteristics and 
treatments were well matched between patient groups. 
We note a significantly lower number of patients with an 
elevated CEA in the overweight/obese patients despite 
similar TNM stage, a result which is likely due to the larger 
vascular volume and consequential haemodilution in obese 
patients (20).
In the current study, BMI appeared to have a stage 
Table 2 Univariate and multivariate analysis for overall survival
Patient characteristics
Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Age
<65 1 <0.0001 1 <0.0001
65–75 1.57 (1.0–2.5) 1.45 (0.9–2.4)
>75 3.84 (2.5–5.8) 3.2 (2.0–5.0)
Male sex 0.77 (0.5–1.1) 0.14
TNM stage 0.033
I 1 0.03 1
II 1.88 (1.2–3.0) 1.85 (1.1–3.1)
III 1.29 (0.9–2.0) 1.81 (1.06–3.1)
High grade tumour 2.27 (1.4–3.6) 0.002 1.77 (1.1–3.0) 0.03
LVI presenta 1.95 (1.3–2.9) 0.001 1.78 (1.3–3.1) 0.001
PNI presentb 1.28 (0.9–1.9) 0.24
Overweight/obese (BMI >25) 0.62 (0.4–0.8) 0.007 0.65 (0.4–0.9) 0.024
Pre-treatment CEA >5 1.30 (0.9–1.9) 0.19
Received adjuvant chemotherapy 0.57 (0.4–0.8) 0.002 0.46 (0.3–0.8) 0.002
Received radiotherapy 0.95 (0.7–1.3) 0.74
a
, 27 results missing; 
b
,
 
16 results missing.
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dependent effect, with improved OS in stage III patients 
(P=0.0009), but not stage I or II. While this result is likely 
to be due, in part, to study power and event numbers, 
similar results have been reported by Kocarnik et al. (21), 
who found that all-cause mortality was higher in overweight 
patients in stage I, but lower in stage III and IV. It is 
postulated that this stage dependent effect is due to the 
reduced metabolic capacity of non-obese patients to cope 
with the more intensive treatment regimens and increased 
metabolic demands of advanced disease (22).  
In addition to this concept of metabolic reserve, there 
are several other key factors that may explain the improved 
outcomes seen in patients with elevated BMIs. Very 
large multi-institutional surgical series have also shown 
improved survival in overweight and obese patients (23). 
This is thought to be driven by a chronic state of low-grade 
inflammation in overweight or mildly obese patients which 
allow a faster response to the stress of surgery (24). More 
intriguingly, hepatic steatosis due to obesity may actually 
protect against the establishment of metastases, with 
reduced rates of hepatic metastases seen in colorectal cancer 
patients with hepatic steatosis (25). There appears to be a 
complex interplay at the molecular level between factors 
affecting obesity, the immune system and oncogenesis which 
has not yet been fully established. Key areas for further 
research include elucidating underlying pathophysiological 
processes, studying the impact of weight change during 
treatments, and identifying more robust markers of 
nutrition in cancer patients.
There are several limitations in our study. This is a 
retrospective study and is limited by the biases inherent 
to this study design. There are likely to be additional 
unmeasured confounders, such as patient comorbidities, 
which have influenced the observed results. BMI is also a 
crude measure of obesity and other more precise measures 
may more accurately evaluate this relationship such as 
mesorectal fat area or sarcopenia (26,27). BMI was also 
measured at diagnosis only, and we were unable to capture 
changes in BMI over time. Of particular importance, 
weight loss prior to diagnosis has been shown to be a poor 
prognostic factor, and is likely to have contributed to the 
inferior outcomes seen in normal weight and under weight 
Figure 1 Association of BMI and (A) overall survival (B) cancer specific survival (C) disease free survival. BMI was associated with improved 
OS (P=0.007) and CSS (P=0.048) but not DFS (0.08).
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patients (28). Lastly, there was only a small number of 
underweight patients limiting conclusions from this patient 
group.
Conclusions
BMI is a key consideration in outcomes for patients with 
locoregional rectal cancer. 
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